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Abstract
We measured the mitochondrial oxidative phosphorylation (mtOXPHOS) activities of all five complexes and determined the
activity and gene expression in detail of the Complex III subunits in human breast cancer cell lines and primary tumors. Our
analysis revealed dramatic differences in activity of complex III between normal and aggressive metastatic breast cancer cell
lines. Determination of Complex III subunit gene expression identified over expression and co-regulation of UQCRFS1
(encoding RISP protein) and UQCRH (encoding Hinge protein) in 6 out of 9 human breast tumors. Analyses of UQCRFS1/RISP
expression in additional matched normal and breast tumors demonstrated an over expression in 14 out of 40 (35%) breast
tumors. UQCRFS1/RISP knockdown in breast tumor cell line led to decreased mitochondrial membrane potential as well as a
decrease in matrigel invasion. Furthermore, reduced matrigel invasion was mediated by reduced ROS levels coinciding with
decreased expression of NADPH oxidase 2, 3, 4 and 5 involved in ROS production. These studies provide direct evidence for
contribution of impaired mtOXPHOS Complex III to breast tumorigenesis.
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Introduction
Mitochondria are essential organelles which perform diverse
cellular functions, including respiration through oxidative phosphor-
ylation (mtOXPHOS), which proceeds through the coordinated
action of 5 inner mitochondrial membrane protein complexes.
During mtOXPHOS, sequential oxidation-reduction reactions at
complexes I (NADH dehydrogenase), II (succinate dehydrogenase),
III (coenzyme Q: cytochrome c-oxidoreductase), and IV (cytochrome
c oxidodase) are coupled to the translocation of protons across the
inner mitochondrial membrane. The resulting electrochemical
gradient is ultimately utilized by complex V (ATP synthase) for the
generation of ATP from ADP and inorganic phosphate [1,2].
Thirteen of the subunits involved in mtOXPHOS are encoded by the
mitochondrial DNA (mtDNA). The remaining subunits (approxi-
mately 85 subunits) are encoded by the nuclear DNA and are
targeted to the mitochondria by a mitochondrial targeting sequence.
Otto Warburg observed that cancer cells have an irreversible
injury to respirationthat leadstodecreased oxidative phosphorylation
(mtOXPHOS) and increased aerobic glycolysis, despite the presence
of sufficient oxygen for aerobic respiration [3,4]. Irreversible injury to
respiration suggested by Warburg involves changes at the genetic
level. These include alterations in nuclear gene expression or
mutations in genes affecting mtOXPHOS. Recent studies have
shown that mutations in mtDNA and/or alterations in mtDNA
content also underlie the irreversible injury to respiration [5–8].
MtOXPHOS complex I-III contains iron-sulfur proteins that
aid in the transfer of electrons within the protein complexes.
Rieske iron-sulfur protein (RISP) in Complex III that binds [2Fe–
2S] cluster via an arrangement of 2 histidines and 2 cysteines [9].
RISP has been shown to be the rate limiting step in Complex III
activity. This protein has been associated with oncogene-induced
senescence [10], however, its role in tumorigenesis is not
described. This study examines mtOXPHOS status in breast
cancer cells and primary breast tumors and determines a role for
complex III in breast tumorigenesis.
Methods
Cell culture conditions
All the cell lines were purchased from ATCC (Manassas, VA).
MCF12A cells were grown in DMEM F12 50/50 media
supplemented with 10% horse serum (MediaTech), 0.1 mg/ml
cholera toxin (Sigma, St. Louis, MO), 20.0 ng/ml epidermal
growth factor (PeproTech, Rocky Hill, NJ), 0.1% penicillin/
streptomycin (MediaTech), 0.5 mg/ml hydrocortisone (Sigma),
1.2 g/L sodium bicarbonate (Sigma) and 10.0 mg/ml insulin
(Sigma). All other cell lines were maintained in DMEM
(MediaTech) with 10% fetal bovine serum (MediaTech) and
0.1% penicillin/streptomycin. r
0 cells were supplemented with
50 mg/ml uridine (Sigma). All cells were maintained in a 37uC,
95% humidity, and 5% carbon dioxide environment.
Western blot analysis
Cells were lysed in RIPA lysis buffer (50 mM tris pH 7.4,
150 mM NaCl, 1 mM PMSF, 1 mM EDTA, 1% triton x-100, 1%
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23846sodium deoxycholate and 0.1% SDS) (all Sigma), with addition of
Protease Inhibitor Cocktail (Roche). Peroxidase labeled anti-mouse
and anti-goat IgG (H+L) were used as secondary antibodies (Vector
Laboratories, Burlingame, CA). Anti-a-tubulin (Molecular Probes,
Eugene, OR) and anti-actin (Santa Cruz Biotechnologies, Santa
Cruz, CA) antibodies were used as loading controls. A premixed
cocktail containing 5 monoclonal antibodies against subunits of
mtOXPHOS complexes (Mitosciences, Eugene, OR) was used to
detect a representative subunit from all 5 mtOXPHOS complexes.
Anti-RISP antibody was from Molecular Probes.
Oxidative phosphorylation enzyme activities
Mitochondria were isolated by differential centrifugation in a
sucrose gradient as described in O’Malley et al. [11]. Protein
concentrations were determined by the Bradford assay. Oxidative
phosphorylation enzyme activities were measured on isolated
mitochondria as previously described [12–14]. All chemicals for
the mtOXPHOS enzyme assays were obtained from Sigma. All
spectrophotometric measurements were performed in 1-ml
cuvettes (1 cm) using Thermo Spectronic Genesis-6 spectropho-
tometer (Waltham, MA). Individual mtOXPHOS complex
activity is expressed as a ratio to MCF12A cells for each individual
respiratory chain complex.
mRNA Expression Level
The study was approved by Roswell Park Cancer Institute
Institutional Review Board, permit number I1085M. Consent from
patients was not needed,as the anonymous tissue samples were used
for study. These samples were collected by the biorepository
resource facility ofthe Roswell Pak Cancer Institute andprovided to
us under IRB approved permit number I1085M. RNA from breast
and normal tissue samples was reverse transcribed using Superscript
III first strand kit (Invitrogen). The RNA was isolated from cell lines
by Trizol extraction according to the manufacturer’s protocol
(Invitrogen) and reverse transcribed using the Superscript III First
Strand kit (Invitrogen). Complex III mRNA expression was
determined using GoTaq Green 2X Master Mix (Progmega,
Madison, WI) with a thermocycler reaction with 1 cycle of 96uC for
2 min; 26–28 cycles of 96uC for 30 s, 60uC for 30 s, 72uC for 30 s; 1
cycleof72uCfor10:00.PrimersforComplexIIIarelisted intable1.
Expression level of NOX1-5 in 143B RISP knock-down clones was
measured as described in Graham et al. [15].
Immunohistochemistry of RISP protein
The study was approved by Roswell Park Cancer Institute
Institutional Review Board, permit number I1085M. Consent from
p a t i e n t sw a sn o tn e e d e d ,a st h ea n o n y m o u st i s s u ea r r a ys l i d ef r o mt h e
Cooperative Human Tissue Network (CHTN) and Breast Cancer
Program 1 of the National Cancer Institute of Health (Bethesda, MD)
was used for immunohistochemistry (IHC). The slide contained
benign breast tissue (n=15), Ductal carcinoma in situ (DCIS; n=12),
Invasive ductal carcinoma (IDC; n=13), invasive lobular carcinoma
(ILC; n=7) and metastatic breast carcinoma in lymph nodes (LNM;
n=7). A section from formalin-fixed, paraffin-embedded benign
breast tissue slide was used as a positive control, and characterization
of the lesions and grading of the tumors was done by a pathologist.
The immunohistochemistry protocol described in Desouki et al., [16]
was applied with modifications. Briefly, the slides were de-paraffinized
by incubation in xylene and ascending grades of alcohol. Antigen
retrieval was done by heating in citrate-based, antigen unmasking
solution for 30 minutes at 98uC, incubated in 3% hydrogen peroxide
for 10 minutes, blocked with blocking peptide for 30 minutes,
incubated with anti-RISP antibody in a dilution of 1:100 overnight at
room temperature, followed by incubation with secondary anti-mouse
antibody for 30 min and another 30 min with the Vectastatin ABC kit
(Vector Laboratories). Color was developed by incubating slides with
peroxidase substrate solution followed by counterstaining with
hematoxylin. Sections from breast carcinoma cases were also
incubated with secondary antibody to check for nonspecific binding.
All sections were examined with Olympus BX50 microscope. The
pictures were taken with an Olympus DP 70 connected to DP
Controller software (Olympus, Center Valley, PA). Scoring of
immunoreactivity was considered to be negative or positive, with
the same parameters we described (score + = , 10% positive, score
++ = 10–50% positive and score +++ = . 50% positive) [16].
shRNA knock-down of RISP protein
Expression of RISP was knocked-down using short-hairpin
RNAs in a retroviral RNAi-Ready pSIREN-RetroQ vector kindly
provided by Dr. Navdeep Chandel (Northwestern University
Medical School). Two sequences were used for targeting RISP
mRNA; RISP #25 9AAUGCCGUCACCCAGUUCGUU-39 and
RISP #11 59-CCUACAUCCCGAUCGAUGAUG-39 [17]. As a
control, pSIRN-RetroQ containing an shRNA sequence against
Drosophila HIF (59-CCUACAUCCCGAUCGAUGAUG-39) was
used. Viral stocks were produced by transfecting Phoenix cells (293
packaging cells) with the pSIREN vectors using FuGene HD
Transfection reagent (Roche). Virus was harvested 24 and 48 h
after transfection. Cells were transduced with the virus in the
presence of 4 mg/ml polybrene (Sigma) and stably transduced cells
were selected for in puromycin (Sigma).
Mitochondrial membrane potential and ROS
measurements
Mitochondrial membrane potential was assessed by labeling the
cells with 100 nM tetramethylrhodamine, ethyl ester, perchlorate
Table 1. Primers for PCR of Complex III subunits.
Gene Name Primer Sequence Direction
UQCRFS1 59-GGCAACGGCAGTAATAACCA-39 Forward
59-CCCACACAGACATCAAGGTG-39 Reverse
UQCRH 59-ACTGGAGGACGAGCAAAAGA-39 Forward
59-TGATGCCCAGATGATGAAGA-39 Reverse
CYC1 59-CCAAAACCATACCCCAACAG-39 Forward
59-TATGCCAGCTTCCGACTCTT-39 Reverse
UCRC 59-CTTCAAAGCCCTCTGCAAAC-39 Forward
59-GCCCAAGACAATTCTTCCAA-39 Reverse
UQCRQ 59-AGTGCAGTGGTGTGATCTCG-39 Forward
59-CTGTGCCCATTTCCTCATCT-39 Reverse
UQCR 59-GAAACCCACAGCTCAGCTTC-39 Forward
59-AGACTTCTCAGGGTGGCTCA-39 Reverse
CYTB 59-TGAAACTTCGGCTCACTCCT-39 Forward
59-AATGTATGGGATGGCGGATA-39 Reverse
UQCRB 59-TTCTCTGTTCGCGATGTGAC-39 Forward
59-GCTGCATCCACAGACTTCAA-39 Reverse
UQCRC1 59-AATGGGGCAGGCTACTTTTT-39 Forward
59-GGTCAAGTCTGCACGAGACA-39 Reverse
UQCRC2 59-CAAAGTTGCCCCCAAACTTA-39 Forward
59-AGCCATGTTTTCCCTTGTTG-39 Reverse
doi:10.1371/journal.pone.0023846.t001
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reactive oxygen species (ROS) production by labeling with 10 mM
dihydroethidium (DHE) (Molecular Probes) for 40 min. Fluores-
cence of both dyes were analyzed on a FACSCalibur flow
cytometer (Becton Dickinson). 10,000 events were collected for
each sample. Mitochondrial membrane potential and ROS levels
were expressed as mean fluorescence intensity (MFI), which was
calculated by WinList software (Verity Software House).
Apoptosis measurement
The apoptotic fraction of cells was determined by measuring the
percent of cells that had subdiploid DNA content (SubG1 Fraction).
Cells were harvested, fixed with cold 70% ethanol, and washed with
0.5% BSA (Sigma). DNA was stained with propdium iodide (Sigma)
in 0.2% sodium citrate (Sigma), 0.2 mg/ml RNase A (Sigma), and
0.2% NP-40 (Sigma) for 30 min at 4uC in the dark. DNA content
was read on the FL2 channel of a FACSCalibur flow cytometer.
50,000 events were collected for each sample.
Matrigel invasion
In vitro invasion was measured using Boyden matrigel chambers
(Becton Dickinson, Franklin Lakes, NJ). Cells were serum starved
for 4 h prior to harvesting. Cells were plated in the upper chamber
with DMEM containing 0.1% BSA, while NIH-3T3 conditioned
media containing 10% FBS was used as a chemoattractant in the
lower chamber. Cells were incubated for 24 h and stained with the
Diff-Quik Stain kit (Dade Behring, Newark, DE).
Results
Mitochondrial oxidative phosphorylation defects in
breast cancer cells
To determine the defect in oxidative phosphorylation in breast
cancer cells we measured the changes in gene expression
associated with mtOXPHOS complexes. We also measured the
enzymatic activities of the various complexes. Functional analysis
was performed by determining the mitochondrial membrane
potential and intracellular ROS levels. MCF12A cell line, an
immortalized, non-transformed cell line, was used as a control.
Breast cancer cell lines demonstrating different levels of tumor-
genicity were used for analysis. These cell lines include MCF7,
T47D, SkBR3, and MDA-MB-231.
Our study demonstrates a decreased expression of subunits of
mtOXPHOS complexes in breast cancer cells as assessed by western
blot (Figure 1A). MCF7 cells show a decrease in Complexes II, III
and V; T47D cells have a decrease in expression of Complexes I and
III; SKBr3 cells show a decrease in expression of Complex III, IV
and V; MDA-MB-231 has a decrease inComplexes I, III, IV and V.
The observed decrease in gene expression of mtOXPHOS subunits
correlateswithadecreaseinindividualcomplexactivities(Figure1B-
F). Complex I activity is decreased about 5-fold in T47D cells but
only about 20% in SKBr3 and MDA-MDA-MB-231 cells
(Figure 1B). Complex II activity is decreased in MCF7, T47D,
and MB231 cells (Figure 1C). Complex III activity is decreased in
MCF7and T47Dcells,increasedinSKBr3cells,and non-detectable
in MDA-MB-231 cells (Figure 1D). Complex IV activity is
significantly decreased in MCF7, SKBr3, and MDA-MB-231 cells,
and slightly increased in T47D. Complex V activity is increased in
T47D cells and in contrast complex IV activity is decreased more
than 5-fold in MDA-MB-231 cells. Interestingly, MDA-MB-231 cell
line which is the most aggressive breast cancer cell line harbored the
most mtOXPHOS defect compared to MCF12A cells. Except for
MCF7 all other cell lines higher mitochondrial membrane potential
(Figure 1G). ROS levels as measured by DHE oxidation was about
two fold less in MCF7 cells while ROS level in SKBr3 and T47D
cells was increased when compared to MCF12A (Figure 1H).
Together these data suggest that mtOXPHOS defect is a common
and consistent feature of breast cancer cells.
Changes in Complex III subunit expression in breast
cancer
Above study identified a dramatically reduced level of Complex
III activity in aggressive breast cancer cell line MDA-MB-231. We
therefore focused on analysis of Complex III in primary breast
tumors. Complex III is a 248 kDa protein complex that comprised
of 11 subunits from 10 gene products. The 11
th subunit is comprised
of the mitochondrial targeting sequence of the RISP protein which
is cleaved and inserted into the transmembrane domainof Complex
III. By RT-PCR we measured expression of the 10 subunits in 5 sets
of matched normal and primary breast tumors derived from same
patient (Figure 2A). In all 5 cases, UQCRFS1 (RISP protein) gene
expression was higher in the breast tumor when compared to its
normal breast tissue counterpart. Importantly, similar pattern of
gene expression was noticed in case of UQCRH (encoding hinge
protein). With the exception of tumor sample T2 and T4, there was
no differencein expression of CYC1, UCRC, UQCRQ, UQCR, CYTB,
UQCRB, UQCRC1 UQCRC2 and UQCRQ in the original 5 sets
(N1T1 to N5T5, Figure 2A). Additional breast tumor analyses
reveal that the UQCRFS1 and UQCRH genes were overexpressed. A
total of 8 out of 9 breast tumors show coordinate regulation of
UQCRFS1 and UQCRH suggesting a common factor involved in
transcriptional regulation of these two genes.
The RISP subunit (encoded by UQCRFS1)i sa ni r o n - s u l f u r
protein that accepts electrons from ubiquinol and transfers them to
cytochrome c. This reaction acts as the rate limiting step for electron
flow through Complex III. Because UQCRFS1 was overexpressed in
small set (9 samples), we quantified its expression in an additional 40
breast tumors. Figure 2C demonstrate that UQCRFS1 was
overexpressed in 14 out 40 (35%) samples. We also measured
UQCRFS1 expression at protein level. Using the tissue microarrays
with several breast corebiopsies from different cases, we screened for
RISP protein expression in a relatively large number of cases under
the same experimental conditions (Figure 3A and B). RISP was
mildly expressed (score +) in one case, moderately expressed (score
++) in 3 cases and highly expressed (score +++)i n2c a s e so fb e n i g n
breasttissuefrom subjectswithoutbreast carcinoma.Examinationof
the breast tumor sections revealed that 100% of benign breast
carcinomas, ductal carcinoma in situ (DCIS),i n v a s i v ed u c t a l
carcinoma (IDC), invasive lobular carcinoma (ILC) and lymph node
metastases (LNM) have high expression of RISP. Interestingly, RISP
expression in benign glands is lower when compared to matched
DCIS cells in cases containing both components in the same tissue
core. Negative control sections incubated with secondary antibody
showed no reaction. We conclude that RISP is overexpressed in
significant number of breast tumors and that its expression does not
correlate with tumor grade.
UQCRFS1 and UQCRH over expression in variety of tumor
types
The above study suggests impaired regulation of RISP and
Hinze Complex III subunits in breast tumors. We determined if
expression of UQCRFS1 (encoding RISP protein) and UQCRH
(encoding Hinge) was also increased in other cancers. Figure 4
demonstrates over expression of UQCRFS1 in blood (myeloma)
[18], lung (squamous cell lung carcinoma) [19], throat (oropha-
ryngeal carcinoma) [20], kidney (renal oncocytoma) [21], blood
(B-cell ALL) [22], parathyroid (parathyroid gland adenoma) [23],
and bladder (infiltrating bladder urothelial) carcinomas [24]. Our
study also revealed increased expression of UQCRH in myeloma
[18], lung tumors [19], embryo (seminoma) [25], prostate tumors
Complex III and Breast Cancer
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bladder (infiltrating bladder urothelial) carcinoma [24]. We
conclude that Complex III subunits encoded by UQCRFS1 and
UQCRH are overexpressed in a variety of primary tumors derived
from different organs and that UQCRFS1 and UQCRH regulated
in myeloma, lung and bladder cancers.
Figure 2. Altered Complex III gene expression in matched normal and tumor human breast tumors. A. UQCRFS1-Ubiquinol-cytochrome
c reductase, Rieske iron-sulfur polypeptide 1; UQCRH-Ubiquinol-cytochrome c reductase hinge protein; CYC1-Cytochrome c-1; UCRC-Ubiquinol-
cytochrome c reductase subunit X.; UQCRQ-Ubiquinol-cytochrome c reductase subunit VII; UQCR-Ubiquinol-cytochrome c reductase subunit XI; CYTB-
Cytochrome b; UQCRB-Ubiquinol-cytochrome c reductase binding protein; UQCRC1-Ubiquinol-cytochrome c reductase core protein I; UQCRC2-
Ubiquinol-cytochrome c reductase core protein II. Actin serves as a loading control. Subunits labeled in green are located in the intermembrane
space, subunits labeled in red are transmemebrane, and subunits labeled in blue are located in the matrix. B. Coregulation of UQCRFS1 and UQCRH
expression in matched normal and tumor breast tissue. C. Quantitative RT-PCR analyses of UQCRFS1 expression in matched normal and tumor breast
tissue.
doi:10.1371/journal.pone.0023846.g002
Figure 1. Changes in OXPHOS subunit gene expression and activity in breast cancer cells. A. Western blot analysis of a representative
subunit from each complex. Ponceau S staining serves as a loading control. Oxidative phosphorylation enzyme activities were measured on isolated
mitochondrial protein. B. Complex I activity was measured as the rotenone inhabitable rate of NADH oxidation. C. Complex II activity was measured
by the succinate induced rate of reduction of DCIP. D. Complex III activity was measured as the rate reduction of cytochrome c (III) when stimulated
with CoQ2H2. E. Complex IV activity was measured as the rate of cytochrome c (II) oxidation. F. Complex V activity was measured by the oxidation of
NADH in the presence of pyruvate kinase/lactic dehydrogenase and PEP. G. Mitochondrial membrane potential was measured by TMRE fluorescence.
H. Intracellular ROS was measured by DHE oxidation. Data are expressed as the mean ratio to MCF12A + 1 SEM, * p,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0023846.g001
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23846Figure 3. UQCRFS1/RISP expression in primary breast tumors. A. Representative images of IHC performed on a breast tissue array (I. Benign
breast tissue incubated with secondary antibody used as a negative control; II. Benign breast tissue with no carcinoma; III. Ductal carcinoma in situ (DCIS); IV.
Breast invasive ductal carcinoma (IDC); V. Invasive lobular carcinoma (ILC); VI. Metastatic breast adenocarcinoma in lymph nodes (LNM)). IHC was done with
an anti-RISP antibody and visualized using DAB with hematoxylin counterstain.B. Graph representing semi-quantitative scoring of immunoreactivity for RISP
expression in benign breast, ductal carcinoma in situ (DCIS), invasive carcinomas and metastatic breast carcinoma in lymph nodes (LN metastasis). IHC
analysis was done on tissue array containing 54 breast tissue cores with anti-RISP antibody.Note high expression (score +++) of RISP protein in DCIS, invasive
primary tumor, and metastatic breast carcinoma compared to benign breast tissue. RISP protein was visualized using DAB with hematoxylin counterstain.
doi:10.1371/journal.pone.0023846.g003
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cancer cells
In order to define RISP associated mitochondrial function and
its role in breast cancer, we knockdown this protein in MCF7, a
RISP overexpressing cell line. When MCF7 cells were transiently
transduced with shRNA directed towards UQCRFS1, we
observed a 75% decrease in RISP expression (Figure 5A). RISP
knockdown led to decrease in mitochondrial membrane potential
when compared to the control (Figure 5B). This trend is also
observed in ROS production (Figure 5C). These results suggest
that RISP is essential for maintaining proper mitochondrial
function. To determine if a reduced RISP expression results in
reduced tumor promoting properties we measured invasion of
matrigel in vitro in a Boyden chamber. There was a significant
Figure 4. Altered Complex III expression in variety of tumors. Oncomine database analysis of UQCRFS1 (A) and UCQRH (B) upregulation in
normal (N) versus tumor (T) human tissue. A. Increased UQCRFS1 expression in blood (myeloma) [18], lung (squamous cell lung carcinoma) [19],
throat (oropharyngeal carcinoma) [20], kidney (renal oncocytoma) [21], blood (B-cell ALL) [22], parathyroid (parathyroid gland adenoma) [23], and
bladder (infiltrating bladder urothelial carcinoma) [24]. B. Increased UQCRH expression in blood (myeloma) [18], lung (squamous cell lung carcinoma)
[19], embryo (seminoma) [25], prostate (prostate adenocarcinoma) [26], pancreas (pancreatic adenocarcinoma) [27], brain (glioblastoma) [28], and
bladder (infiltrating bladder urothelial carcinoma) [24].
doi:10.1371/journal.pone.0023846.g004
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(Figure 5D). These studies suggest that RISP contributes to the
invasive potential of breast cancer cells.
RISP knock-down inhibits matrigel invasion of other
transformed cells
The above study shows RISP regulates mitochondrial function.
We asked whether mitochondrial dysfunction effects RISP
expression. We determined RISP expression in osteosarcoma cells
(143B) and it derivative cell line devoid of mitochondrial DNA (r
0
cells). RISP protein was undetected in 143B cells devoid of
mtDNA (Figure 6A). To determine if the RISP knockdown in
osteosarcoma cells recapitulate the effect we saw in breast cancer
cells we used 143B cells (Figure 6B). A decrease in RISP expression
in 143B cells led to a significant increase in resistance to apoptosis
(Figure 6C). There was also a decrease in in vitro invasion as
measured by a Matrigel invasion assay (Figure 6D). We conclude
that RISP plays an important role in development of other tumors.
RISP regulates NADPH oxidase expression
Above study suggest that RISP expression is associated with
production of ROS. NADPH oxidase (NOX) proteins are well
known producers of ROS in cells. So we determined whether RISP
associated ROS production was mediated by NOX proteins.
Figure 7 shows that RISP knockdown leads to decreaseinexpression
of NOX2, NOX3, NOX4,a n dNOX5. Interestingly, NOX1 expression
was unchanged. This study suggests that a defect in Complex III
influences expression of ROS producing NOX proteins.
Discussion
In this study we examined the OXPHOS function in breast
cancer cells. The activity of mtOXPHOS complexes III was
reduced significantly in the metastatic and aggressive breast cancer
cell lines. Detailed examination of Complex III showed that the
iron-sulfur RISP protein, a vital part of electron transfer through
Complex III, is up-regulated in human breast tumors (Figure 2).
To determine RISP is causally related to breast tumorigenesis, we
used shRNA against RISP to knock-down its expression. This
resulted in a decrease in invasiveness in breast (MCF7) and
osteosarcoma (143B) cells as measured by the matrigel invasion
assay (Figure 5D and 6D). Our study is supported by previous
report suggesting a decrease in matrigel invasion due to defect in
OXPHOS complex [29].
Knock-down of RISP protein caused altered mitochondrial
function (Figure 5). Electron transfer to the iron-sulfur cluster in
RISP is the rate-determining step in Complex III activity [9].
Previous experiments have shown that Complex III proteins that
are lacking the Fe-S cluster in the RISP subunit have an open
proton channel through the complex allowing for the unregulated
translocation of protons [30,31]. This could potentially explain the
decrease in mitochondrial membrane potential seen when RISP is
knocked-down in MCF7 cells. RISP protein was absent in cells
devoid of mitochondrial DNA (Figure 6A). Our previous study
suggest that the core 1 subunit (UQCRQ1) expression of Complex
III was decreased in cells devoid of mtDNA, however, when
mtDNA was replaced in these cells the expression levels of the core
1 subunit recovered back to the level of wild-type cells [32].
Consistent with our study showing overexpression of RISP in
breast tumors and other tumors, previous studies report genetic
amplification of the UQCRFS1/RISP gene not only in breast but
also in ovarian cancers and in leukemia [33–35]. UQCRFS1/
RISP amplification was found to be in 12.8% of breast tumors
examined by Ohashi et al. [35] and 13.6% ovarian cases reported
by Kaneko et al. [34]. Data presented in this study suggest a
correlation between the mtOXPHOS defects with the severity of
Figure 5. UQCRFS1/RISP knock-down results in mitochondrial dysfunction. A. RISP levels in MCF7 cells 3 day after transduction with anti-
RISP shRNA (clone #11). pSiren was used as the vector control. B. Mitochondrial membrane potential of RISP knockdown cells. Membrane potential
was measured by TMRE fluorescence. C. ROS levels in RISP knockdown cells. ROS was measured by oxidation of DHE. E. Invasion in RISP knockdown
cells. Invasion was measured by a Matrigel invasion assay. Data represent ratio to MCF7 + 1 SEM, * p,0.05, ** p,0.005.
doi:10.1371/journal.pone.0023846.g005
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line, MDA-MB-231, contained the most aberrations in mtOX-
PHOS activity. Indeed, Complex III activity was undetected and
complex V activity was reduced to 10% in MDA-MB-231. It is
noteworthy that MDA-MB-231 is a triple negative (ER-, PR- and
HER2-) cell line demonstrated to form highly aggressive breast
tumors. These data suggest that impaired Complex III is involved
in development of breast cancer and that aggressiveness of breast
cancer is associated with type and nature of mtOXPHOS defect.
The mitochondria and NOX family proteins are major sources
of cellular ROS in the cell. NOX proteins are a superoxide
producing family of proteins that traditionally have been thought
to serve as host-defense [36]. Recent studies have shown that
NOX proteins are also expressed in a variety of tissues and play a
role in cellular signaling and tumorigenesis through ROS
production [15,37,38]. We has previously shown that the NOX
proteins are regulated by mitochondrial dysfunction [16] and are
also associated with breast cancer [15]. Analyses of NOX in RISP
knockdown cells revealed decreased level of NOX expression
coinciding with decreased matrigel invasion (Figure 6). These
study suggest NOX mediated ROS may play a role in a key step of
breast tumoroigenesis. In summary, our data suggest that an
impaired Complex III function contributes to the development of
breast cancer.
Figure 7. UQCRFS1/RISP knock-down decreases expression of NADPH oxidase (NOX) genes. RT-PCR analyses of NOX genes in RISP
knockdown cells. Actin served as a loading control.
doi:10.1371/journal.pone.0023846.g007
Figure 6. Lack of UQCRFS1/RISP expression in r
0 cells. A. Western blot analysis of RISP expression in 143B and 143B r
0 osteosarcoma cells.
Tubulin served as a loading control. B. RISP knock-down in 143B cells transduced with either pSiren (control) or shRNA directed against RISP (clone
#2). C. Resistance to apoptosis was measured by analyzing SubG1 fraction by DNA staining with propidium iodide. D. In vitro invasion was measured
by a Matrigel invasion assay in RISP knockdown cells. ** p,0.005 *** p,0.0005.
doi:10.1371/journal.pone.0023846.g006
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